Literature DB >> 8222477

Colchicine disposition in human leukocytes after single and multiple oral administration.

O N Chappey1, E Niel, J L Wautier, P P Hung, M Dervichian, D Cattan, J M Scherrmann.   

Abstract

Inasmuch as leukocytes were reported to be an active pharmacologic compartment, colchicine disposition was determined in plasma, granulocytes, and mononuclear cells in healthy volunteers after 1 mg oral single and multiple doses. After the single dose, maximal colchicine concentration was observed at 1 hour in plasma and 47 hours later in leukocytes. This delay was confirmed by the slow accumulation of colchicine by lymphocytes in culture. In the multiple-dose study, mean granulocyte colchicine concentration (20 to 53 ng/10(9) cells) were twofold higher than in mononuclear cells (9 to 24 ng/10(9) cells). Mean predicted colchicine multiple-dose granulocyte and mononuclear cell concentrations were 2.5-fold and ninefold higher, respectively, than those measured. After the last dose, colchicine decreased, with half-life values between 41 and 46 hours for leukocytes and 49 hours for plasma. This study validates leukocytes as a microcompartment whose kinetics correlates with colchicine biologic effects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8222477     DOI: 10.1038/clpt.1993.161

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Oral colchicine (Colcrys): in the treatment and prophylaxis of gout.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

Review 2.  Colchicine: old and new.

Authors:  Anastasia Slobodnick; Binita Shah; Michael H Pillinger; Svetlana Krasnokutsky
Journal:  Am J Med       Date:  2014-12-30       Impact factor: 4.965

Review 3.  Update on colchicine and its mechanism of action.

Authors:  Yair Molad
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

4.  Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease.

Authors:  Sergio Muntoni; Marcos Rojkind; Sandro Muntoni
Journal:  World J Gastroenterol       Date:  2010-06-21       Impact factor: 5.742

Review 5.  Colchicine for secondary prevention of cardiovascular disease.

Authors:  Stefan M Nidorf; John W Eikelboom; Peter L Thompson
Journal:  Curr Atheroscler Rep       Date:  2014-03       Impact factor: 5.113

6.  P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.

Authors:  X Declèves; O Chappey; B Boval; E Niel; J M Scherrmann
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

7.  Colchicine concentration in leukocytes of patients with familial Mediterranean fever.

Authors:  O Chappey; E Niel; M Dervichian; J L Wautier; J M Scherrmann; D Cattan
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

Review 8.  [Evidence-based treatment recommendations for familial Mediterranean fever : A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

Authors:  T Kallinich; N Blank; T Braun; E Feist; U Kiltz; U Neudorf; P T Oommen; C Weseloh; H Wittkowski; J Braun
Journal:  Z Rheumatol       Date:  2019-02       Impact factor: 1.372

Review 9.  Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.

Authors:  George Nuki
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 10.  Colchicine in the Management of Acute and Chronic Coronary Artery Disease.

Authors:  Nadia Bouabdallaoui; Jean-Claude Tardif
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.